Stem Cell Therapy for ALS / Motor Neurone Disease in 2026

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND), is a progressive neurodegenerative condition in which motor neurons in the brain and spinal cord progressively die, leading to muscle weakness, atrophy, and eventually paralysis. Median survival from diagnosis remains around 3-5 years, although significant variation exists. Approximately 450,000 people worldwide live with ALS at any given time.

Conventional treatment in 2026 has improved modestly. Riluzole and edaravone provide small but measurable benefits in survival and functional decline. Sodium phenylbutyrate-taurursodiol (Relyvrio) was approved and then withdrawn following negative confirmatory trials. Tofersen has been approved for the small subset of patients with SOD1 gene mutations. Multidisciplinary clinical care with respiratory, nutritional, physiotherapy, speech, and palliative support significantly improves quality of life and survival. But there is no cure, and most patients face progressive decline despite optimal care.

Stem cell therapy has been intensely researched in ALS for over two decades. The biological rationale is strong: MSCs offer anti-inflammatory, neuroprotective, and growth-factor-secreting effects relevant to the multiple pathological mechanisms in ALS. However, despite many trials, no stem cell therapy has yet shown definitive disease-modifying benefit in large Phase 3 studies. This guide presents the honest 2026 picture.

Effective ALS protocols typically prioritise intrathecal delivery — direct injection of MSCs into the cerebrospinal fluid via lumbar puncture — to provide cells direct access to the central nervous system. Most protocols combine intrathecal injection with intravenous infusion to address both CNS and systemic inflammation. Cell doses are individualised, with intrathecal doses typically in the range of 50-100 million cells and IV doses of 100-200 million cells.

Most ALS patients receive 2-3 infusions over a 5-7 day stay, with consideration of repeat treatment every 3-6 months for as long as the patient remains stable enough to tolerate the protocol and continues to derive benefit. The intrathecal procedure is performed in a hospital setting under specialist supervision; the IV infusions are outpatient. Most patients require coordination of respiratory and mobility support during their stay.

Pre-treatment evaluation includes detailed neurological assessment (ALSFRS-R, respiratory function, swallowing, cognitive screening), imaging review, and detailed family discussion about goals and realistic expectations. We do not encourage patients with very advanced disease, severe respiratory compromise, or short expected survival to travel for treatment when the burden likely outweighs the realistic potential benefit.